U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C26H24N6O2S2
Molecular Weight 516.638
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of SRT-2104

SMILES

CC1=C(SC(=N1)C2=CC=CN=C2)C(=O)NC3=CC=CC=C3C4=CN5C(CN6CCOCC6)=CSC5=N4

InChI

InChIKey=LAMQVIQMVKWXOC-UHFFFAOYSA-N
InChI=1S/C26H24N6O2S2/c1-17-23(36-25(28-17)18-5-4-8-27-13-18)24(33)29-21-7-3-2-6-20(21)22-15-32-19(16-35-26(32)30-22)14-31-9-11-34-12-10-31/h2-8,13,15-16H,9-12,14H2,1H3,(H,29,33)

HIDE SMILES / InChI

Molecular Formula C26H24N6O2S2
Molecular Weight 516.638
Charge 0
Count
MOL RATIO 1 MOL RATIO (average)
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description

SRT2104, also known as GSK2245840, is a novel, first in class, highly selective small molecule activator of the NAD + dependent deacetylase SIRT1. SIRT1 has been suggested as putative therapeutic target in multiple age-related diseases including type 2 diabetes and dyslipidemias. SRT2104 in the phase II of clinical trial to treat type 2 diabetes mellitus and psoriasis also in the phase I for its use in case of colitis. Also was reported, that we report that SRT2104, penetrated the blood-brain barrier, attenuated brain atrophy, improved motor function, and extended survival in a mouse model of Huntington's disease.

CNS Activity

Originator

Approval Year

Targets

Primary TargetPharmacologyConditionPotency

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Unknown
Primary
Unknown
Primary
Unknown

Cmax

ValueDoseCo-administeredAnalytePopulation
261.2 ng/mL
3 g 1 times / day multiple, oral
SRT-2104 plasma
Homo sapiens

AUC

ValueDoseCo-administeredAnalytePopulation
1573 ng × h/mL
3 g 1 times / day multiple, oral
SRT-2104 plasma
Homo sapiens

T1/2

ValueDoseCo-administeredAnalytePopulation
14.6 h
3 g 1 times / day multiple, oral
SRT-2104 plasma
Homo sapiens

PubMed

Patents

Sample Use Guides

In Vivo Use Guide
oral administration (10–300 mg/kg/day; for five to 28 days)
Route of Administration: Oral
In Vitro Use Guide
C2C12 cells were treated with vehicle (0.1% DMSO) or 3 μM SRT2104 for 24 h. RelA/p65 protein levels were upregulated in C2C12 myoblasts in response to SRT2104 treatment. SRT2104 led to lower acetylation of RelA/p65 in C2C12 myoblasts, likely due to selective activation of SIRT1
Substance Class Chemical
Record UNII
4521NR0J09
Record Status Validated (UNII)
Record Version